Opinion|Videos|December 24, 2025
3-Year Data From SEQUOIA Arm D: Zanubrutinib Plus Venetoclax in Treatment-Naive, High-Risk CLL
Author(s)Marc S. Hoffmann, MD
A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective time-limited therapy options.
Advertisement
Marc S. Hoffmann, MD, highlights 3-year results from SEQUOIA trial arm D, a nonrandomized cohort that examined a fixed-duration combination of the BTK inhibitor zanubrutinib plus the BLC2 inhibitor venetoclax in patients with treatment-naive CLL with del(17p) and/or TP53 mutation, but not both. Hoffmann describes efficacy outcomes and discusses continuous and fixed-duration therapy options in this setting.
Advertisement
Related to this article
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Eftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors for treatment with pembrolizumab.
Advertisement
Advertisement
Trending on Targeted Onc
1
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
4
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
5